Simponi
Janssen abandons Simponi application
May 23, 2014Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis
Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …
Merck: ‘2014 revenues will be down’
February 7, 2014Sales and Marketing Frazier, Merck, Simponi, Singulair, isentress, q4, results
Merck is the latest pharma company to release figures suggesting 2013 was more of a struggle than it would like, …
MSD sways NICE with Simponi patient access scheme
August 26, 2011Sales and Marketing NICE, Simponi, ankylosing spondylitis
A patient access scheme which lowers Simponi’s cost has led to Merck Sharp and Dohme’s drug being given the thumbs …
Price concession helps change NICE’s mind on Simponi
May 13, 2011Sales and Marketing NICE, Simponi, TNF, merck sharp and dohme
NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …
J&J and Merck reach compromise on arthritis drug rights
April 19, 2011Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi
Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
J&J hit by another string of product recalls
February 21, 2011Manufacturing and Production J&J, JJ, Johnson & Johnson, Simponi, golimumab, manufacturing compliance, pharma recalls
There seems to be no end to the quality troubles plaguing Johnson & Johnson, with several more recalls to report, …
Ulcerative colitis market set to double by 2018
February 12, 2010Sales and Marketing Humira, Simponi, TNF, ulcerative colitis
The market for ulcerative colitis drugs is set to double over the ten years to 2018 when it will hit …
Simponi approved in Europe
October 8, 2009Sales and Marketing RA, Simponi, TNF
Rheumatic disease drug Simponi has received marketing approval for Europe, where it will be marketed by Schering-Plough.The drug is indicated …
Simponi approved in Canada
April 16, 2009Research and Development, Sales and Marketing J&J, JJ, Simponi
Johnson & Johnson's monoclonal antibody Simponi has been given regulatory approval in Canada.Simponi (golimumab) has been given the green light …
Latest content
Five Facts about cardiovascular disease
